MicroRNA-92a promotes cell viability and invasion in cervical cancer via directly targeting Dickkopf-related protein 3

SHENGTIAN LUO, NA LI, SHAOHUA YU, LICHUN CHEN, CHUNYING LIU and JIAWEI RONG

Department of Obstetrics and Gynecology, General Hospital of Daqing Oil Field, Daqing, Heilongjiang 163001, P.R. China

Received April 29, 2016; Accepted March 10, 2017

DOI: 10.3892/etm.2017.4586

Abstract. MicroRNA-92a (miR-92a) was recently reported to have an oncogenic role in cervical cancer; however, the underlying mechanism remains largely unclear. The present study aimed to investigate the expression, clinical significance and regulatory mechanism of miR-92a in cervical cancer. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) data indicated that miR-92a was significantly upregulated in cervical cancer tissues compared with matched adjacent non-tumor tissues (P<0.01). High expression of miR-92a was significantly associated with poor differentiation (P=0.031), advanced clinical stage (P=0.011) and lymph node metastasis (P=0.014), but not associated with age, tumor size and distant metastasis. Knockdown of miR-92a significantly inhibited the viability and invasion of cervical cancer HeLa cells, while overexpression of miR-92a significantly enhanced HeLa cell viability and invasion (P<0.01). Luciferase reporter assay identified Dickkopf-related protein 3 (DKK3) as a target gene of miR-92a, and the protein expression of DKK3 was negatively regulated by miR-92a in HeLa cells. Furthermore, overexpression of DKK3 significantly eliminated the stimulative effects of miR-92a in HeLa cells. Additionally, DKK3 was significantly downregulated in cervical cancer tissues compared with adjacent non-tumor tissues (P<0.01), inversely correlated to the miR-92a levels in cervical cancer tissues (P<0.01). In summary, the present study indicated that miR-92a promotes cell viability and invasion in cervical cancer, partly at least, via inhibiting the protein expression of DKK3. Therefore, the present study highlights the clinical significance of the miR-92a/DKK3 axis in cervical cancer.

Introduction

Cervical cancer is the third most common cancer, as well as the fourth most frequent cause of cancer-related mortality in women worldwide (1). According to recent global cancer statistics, there are ~530,000 new cervical cancer cases annually, most of which occur in developing countries, including China (1). Despite improvements in surgery combined with radiotherapy and/or chemotherapy, the prognosis for patients with cervical cancer remains poor, primarily due to its recurrence and ability to metastasize (2). Studies on the molecular mechanism underlying cervical cancer growth and metastasis are urgently required for the development of effective therapeutic strategies for cervical cancer.

MicroRNA (miR) belong to a class of small non-coding RNA and are critical regulators of gene expression at the post-transcriptional level (3,4). MiR directly bind to the 3′-untranslated region (UTR) of their target mRNA, causing mRNA degradation or translation inhibition (3,4). Through negatively mediating the protein expression of their targets, miR are involved in a variety of biological processes, including cell survival, proliferation, differentiation, apoptosis, migration, autophagy, invasion, angiogenesis and tumorigenesis (3-7). In recent decades, deregulations of various miR have been implicated in the development and malignant progression of cervical cancer, some of which have been suggested to be used as potential diagnostic and therapeutic targets for cervical cancer (8-10). For instance, downregulation of miR-143 in cervical cancer promotes apoptosis and inhibits tumor formation by targeting B-cell lymphoma-2 (11). Furthermore, miR-214 is aberrantly expressed in cervical cancer and inhibits the growth of HeLa cells (12).

Among these cancer-related miR, miR-92a has been demonstrated to possess an oncogenic role in different cancer types, and several targets have been identified (13-15). A previous study indicated that miR-92a promoted the metastasis of colorectal cancer cells through inhibition of phosphatase and tensin homolog, leading to the upregulation of the phosphoinositide 3-kinase/protein kinase B pathway (13). Furthermore, miR-92a was also revealed to promote pancreatic cancer cell proliferation through inhibiting the protein expression of dual specificity phosphatase 10, which enhanced the activation of the c-Jun N-terminal kinase signaling pathway (16). Recently, miR-92a was reported to be upregulated in cervical cancer and involved in promoting cell survival, proliferation, differentiation, apoptosis, migration, autophagy, invasion, angiogenesis and tumorigenesis.
proliferation and invasion by targeting F-Box and WD repeat domain containing 7 (17). As one miR has multiple target genes, whether alternative targets of miR-92a exist in cervical cancer cells still requires further investigation.

In the present study, the expression, clinical significance and regulatory mechanism of miR-92a in cervical cancer was explored. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blotting were used to evaluate mRNA and protein expression. MTT and wound healing assays were used to determine the cell viability and migration. A luciferase reporter gene assay was used to confirm the targeting relationship.

Materials and methods

Tissue collection. The present study was approved by the Ethics Committee of General Hospital of Daqing Oil Field (Daqing, China). A total of 65 primary cervical cancer tissues and their matched adjacent non-tumor tissues were collected at the Department of Obstetrics and Gynecology of General Hospital of Daqing Oil Field between April 2012 and March 2014. All patients enrolled in the study provided written informed consent. The patients with cervical cancer involved in this study were all female, from 41 to 65 years old, and were diagnosed by pathologists at Pathology Department of General Hospital of Daqing Oil Field. Prior to surgical resection, all patients did not receive radiation therapy or chemotherapy. Tissues were immediately snap-frozen in liquid nitrogen after surgical resection, and stored in liquid nitrogen prior to use. The clinical information of patients involved in the present study is summarized in Table I.

Cell culture. The human cervical cancer HeLa cell line was purchased from Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). A total of 1x10⁶ cells were cultured in Dulbecco’s modified Eagle medium (DMEM; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific, Inc.) at 37°C in a humidified atmosphere containing 5% CO₂.

Cell transfection. Lipofectamine 2000 (Thermo Fisher Scientific, Inc.) was used for cell transfection, according to the manufacturer’s instructions. HeLa cells (1x10⁶ cells) were transfected with scramble miR mimic, which was miR-negative control (miR-NC), miR-92a mimic, miR-92a inhibitor, NC inhibitor, or co-transfected with miR-92a mimic (all purchased from Fulengen Co., Ltd., Guangzhou, China) and pcDNA3.1-Dickkopf-related protein 3 (DKK3) expression plasmid (Yearthbio, Changsha, China), respectively. After transfection for 48 h at 37°C, RT-qPCR or western blotting was conducted to examine the mRNA and protein expression levels, respectively, of miR-92a or DKK3.

RT-qPCR. Total RNA from tissues and cell lines was extracted using TRIzol reagent (Thermo Fisher Scientific, Inc.) and converted into cDNA using a PrimeScript 1st Strand cDNA Synthesis kit (Takara Bio, Inc., Otsu, Japan), according to the manufacturer’s instructions. For mRNA expression detection, SYBR Green I Real-Time PCR kit (Biomics Biotechnologies Co., Ltd., Nantong, China) was used to perform qPCR on an ABI 7500 thermocycler (Thermo Fisher Scientific, Inc.), according to the manufacturer’s instructions. GAPDH was used as an internal control. For miR expression detection, qPCR was performed using an miRNA Q-PCR Detection kit (GeneCopeia, Inc., Rockville, MD, USA) on an ABI 7500 thermocycler (Thermo Fisher Scientific, Inc.), according to the manufacturer’s instructions. The U6 gene was used as an internal control. DKK3 forward primer: 5'-AGGACACGCAGCACAATTG-3'; reverse primer: 5'-CCAGTCTGGTGTGTTATCTT-3'. GAPDH forward primer: 5'-GGAGCGAGATCCCTCACAATT-3'; reverse primer: 5'-GGCTGTGTGTCATATCTTCATGG-3'. The reaction conditions were 95°C for 3 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 15 sec. The relative expression was analyzed by the 2-ΔΔCq method (18).

Western blotting. HeLa cells were solubilized in cold radiomunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology, Shanghai, China). The protein concentration was determined using Pierce BCA Protein Assay kit (Thermo Fisher Scientific, Inc.) according to the manufacturer’s instructions, and protein (50 µg) was separated with 10% SDS-PAGE and transferred onto a polyvinylidene difluoride membrane (PVDF; Thermo Fisher Scientific, Inc.). The PVDF membrane was incubated with phosphate-buffered saline (PBS) containing 5% milk (Mengniu Dairy Co., Ltd., Beijing, China) for 3 h at room temperature. After washing three times with

<table>
<thead>
<tr>
<th>Variables</th>
<th>miR-92a expression level</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;55</td>
<td>24</td>
<td>10</td>
</tr>
<tr>
<td>≥55</td>
<td>41</td>
<td>17</td>
</tr>
<tr>
<td>Tumor size, cm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤4</td>
<td>41</td>
<td>15</td>
</tr>
<tr>
<td>&gt;4</td>
<td>24</td>
<td>12</td>
</tr>
<tr>
<td>Differentiation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well-moderate</td>
<td>46</td>
<td>23</td>
</tr>
<tr>
<td>Poor</td>
<td>19</td>
<td>4</td>
</tr>
<tr>
<td>Clinical stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-II</td>
<td>44</td>
<td>23</td>
</tr>
<tr>
<td>III-IV</td>
<td>21</td>
<td>4</td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>39</td>
<td>21</td>
</tr>
<tr>
<td>Yes</td>
<td>26</td>
<td>6</td>
</tr>
<tr>
<td>Distant metastasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>56</td>
<td>25</td>
</tr>
<tr>
<td>Yes</td>
<td>9</td>
<td>2</td>
</tr>
</tbody>
</table>

miR-92a, microRNA-92a.
MiR-92a is upregulated in cervical cancer and is associated with its malignant progression. To study the role of miR-92a in cervical cancer, RT-qPCR was performed to determine the miR-92a expression levels in a total of 65 primary cervical cancer tissues and their matched adjacent non-tumor tissues. As indicated in Fig. 1, the expression level of miR-92a was significantly increased in cervical cancer tissues compared with adjacent non-tumor tissues (P<0.01). The association between the miR-92a expression levels and the clinical characteristics of cervical cancer were further investigated. All 65 cases of cervical cancer patients were further divided into the high miR-92a level group and low miR-92a level group, according to the mean value of the miR-92a level (1.48) as the cutoff point. As demonstrated in Table I, 38 cases were in the high miR-92a expression group and 27 cases were in the low miR-92a expression group. Furthermore, the increased miR-92a expression was significantly associated with poor differentiation (P=0.031), advanced clinical stage (P=0.011) and lymph node metastasis (P=0.014; Table I); however, no statistically significant association of miR-92a expression was found with age, tumor size and distant metastasis (Table I). These findings suggested that upregulation of miR-92a may contribute to the malignant progression of cervical cancer.
**MiR-92a promotes HeLa cell viability and invasion.** The regulatory role of miR-92a in cervical cancer cell viability and invasion was further studied. Cervical cancer HeLa cells were transfected with miR-92a inhibitor or mimic, and NC inhibitor and miR-NC were used as control groups, respectively. After transfection, RT-qPCR was conducted to examine the miR-92a expression levels. As demonstrated in Fig. 2A and B, transfection with miR-92a inhibitor significantly decreased the miR-92a expression level compared with the NC inhibitor group, whereas transfection with miR-92a mimic led to a significant increase in miR-92a expression level compared with the miR-NC group (both \( P<0.01 \)). MTT assay was then used to examine cell viability. As demonstrated in Fig. 2C and D, knockdown of miR-92a significantly reduced HeLa cell viability, whereas overexpression of miR-92a significantly enhanced HeLa cell viability (\( P<0.01 \)). Similar findings were also observed in the invasion assay, which indicated that miR-92a inhibition significantly reduced HeLa cell invasion, whereas its upregulation significantly promoted HeLa cell invasion (\( P<0.01 \); Fig. 3A and B). Based on these data, the present results demonstrated that miR-92a promotes HeLa cell viability and invasion.

**DKK3 is a target gene of miR-92a in HeLa cells.** As miR function through the inhibition of their target genes, bioinformatics analysis was performed to analyze the targets of miR-92a. As demonstrated in Fig. 4A, DKK3 was identified to be a putative target of miR-92a. The expression levels of DKK3 in HeLa cells were compared. As demonstrated in Fig. 4B, overexpression of miR-92a significantly decreased the protein expression levels of DKK3 (\( P<0.01 \)). However, there was no significant difference in the mRNA expression levels of DKK3 among these groups (Fig. 4D and E). These findings suggest that DKK3 may be a direct target gene of miR-92a.

To further investigate these findings, HeLa cells were co-transfected with WT-DKK3-3'UTR or MUT-DKK3-3'UTR luciferase reporter plasmid (Fig. 5A), and miR-92a mimic or miR-NC, respectively. Luciferase reporter assays demonstrated that the luciferase activity was significantly decreased in HeLa cells co-transfected with miR-92a mimic and luciferase reporter vector containing the WT-DKK3-3'UTR compared with the control group (\( P<0.01 \)). However, no significant difference in activity was observed in HeLa cells co-transfected with miR-92a mimic and luciferase reporter vector containing the MUT-DKK3-3'UTR (Fig. 5B). Therefore, the present findings indicated that DKK3 is a target gene of miR-92a in HeLa cells.

**Overexpression of DKK3 attenuated the stimulative effects of miR-92a on HeLa cell viability and invasion.** As DKK3 has been demonstrated to act as a tumor suppressor in various types of human cancer such as pancreatic cancer and breast cancer (19,20), DKK3 may be involved in the miR-92a-induced invasion and cell viability of HeLa cells. To explore this speculation, miR-92a-overexpressing cervical cancer cells were transfected with pcDNA3.1-DKK3 expression plasmid. As demonstrated in Fig. 6A, the protein expression levels of DKK3 were significantly increased in the miR-92a + DKK3 group compared with the miR-92a group (\( P<0.01 \)). MTT assay and Transwell assay were then used to determine the cell viability.

---

Figure 2. HeLa cells were transfected with miR-92a inhibitor or mimic, and NC inhibitor and miR-NC were used as control groups, respectively. (A and B) Reverse transcription-quantitative polymerase chain reaction was performed to determine the relative mRNA expression levels of miR-92a relative to GAPDH. Data are presented as mean ± standard deviation. (C and D) MTT assay was used to examine cell viability. Data are presented as mean ± standard deviation. **P<0.01 vs. NC inhibitor; ***P<0.01 vs. miR-NC. miR, microRNA; NC, negative control; OD, optical density.
Figure 3. Transwell assay was used to examine cell invasion in HeLa cells transfected with miR-92a (A) inhibitor or (B) mimic. NC inhibitor and miR-NC were used as control groups, respectively. Data are presented as the mean ± standard deviation. *P<0.01 vs. NC inhibitor; **P<0.01 vs. miR-NC. miR, microRNA; NC, negative control.

Figure 4. (A) Targetscan software predicted that DKK3 was a putative target of miR-92a. (B and C) Western blotting and (D and E) reverse transcription-quantitative polymerase chain reaction examined the protein and mRNA expression levels of DKK3 in HeLa cells transfected with scramble miR (miR-NC), miR-92a mimic, NC inhibitor and miR-92a inhibitor, respectively. Data are presented as the mean ± standard deviation. *P<0.01 vs. miR-NC; **P<0.01 vs. NC inhibitor. miR, microRNA; NC, negative control; UTR, untranslated region; DKK3, Dickkopf-related protein 3.
LUO et al: miR-92a PROMOTES CERVICAL CANCER

The data indicated that the viability and invasion of HeLa cells were significantly reduced in the miR-92a + DKK3 group compared with those in the miR-92a group, respectively (P<0.01; Fig. 6B and C). Therefore, overexpression of DKK3 attenuated the stimulative effects of miR-92a on HeLa cell viability and invasion. These
findings suggested that the stimulative effects of miR-92a on HeLa cell viability and invasion may be through the inhibition of DKK3 expression.

**DKK3 is downregulated in cervical cancer tissues and inversely correlated with miR-92a expression.** The expression of DKK3 in cervical cancer tissues was determined. RT-qPCR data indicated that mRNA expression levels of DKK3 were significantly reduced in cervical cancer tissues compared with adjacent non-tumor tissues (P<0.01, Fig. 7A). Furthermore, an inverse correlation was identified between miR-92a and DKK3 expression levels in cervical cancer tissues (Fig. 7B), suggesting that the increased expression of DKK3 may be due to the downregulation of miR-92a.

**Discussion**

The regulatory mechanisms of miR-92a on the proliferation and invasion of cervical cancer cells remains largely unknown. The present findings demonstrated that miR-92a was significantly upregulated in cervical cancer tissues compared with matched adjacent non-tumor tissues, and high miR-92a levels were significantly associated with poor differentiation, advanced clinical stage and lymph node metastasis. Further investigation demonstrated that miR-92a promoted HeLa cell viability and invasion. Furthermore, DKK3 was identified as a direct target of miR-92a, and its protein expression was negatively regulated by miR-92a in HeLa cells. Overexpression of DKK3 eliminated the stimulative effects of miR-92a on HeLa cell viability and invasion. Additionally, DKK3 was significantly downregulated in cervical cancer tissues compared with adjacent non-tumor tissues and inversely correlated to the miR-92a expression levels in cervical cancer tissues.

Aberrant upregulation of miR-92a has been demonstrated in some common human cancers such as rectal cancer and gastric cancer, and generally has an oncogenic role (21,22). MiR-92a was demonstrated to be significantly upregulated in gastric cancer tissues compared with paracancerous normal tissue, and high expression of miR-92a was a significant predictor of shorter survival in stage II and stage III gastric cancer (22). Inhibition of miR-92a with locked nucleic acid was able to prevent cell proliferation and induce cell apoptosis in acute megakaryoblastic leukemia (23). A study by Hu et al (24) also demonstrated that butyrate inhibited colon cancer cell proliferation and induced cell apoptosis via downregulation of miR-92a. These findings suggest that miR-92a may become a potential therapeutic target for cancer treatment. Recently, miR-92a was reported to promote cervical cancer. A study by Zhou et al (17) reported that miR-92a was significantly upregulated in cervical cancer tissues and cell lines. Overexpression of miR-92a significantly enhanced cervical cancer cell proliferation by promoting cell cycle transition from G1 to S phase and promoted cell invasion. A study by Wang et al (25) suggested that upregulation of miR-92a may be used as an important biomarker for oncogenic human papillomavirus infections. In the present study, a significant upregulation of miR-92a expression in cervical cancer tissues compared to matched adjacent non-tumor tissues was also observed. Furthermore, the increased miR-92a expression was significantly associated with poor differentation, advanced clinical stage and lymph node metastasis, suggesting that its upregulation may contribute to the malignant progression of cervical cancer. In vitro study further identified that knockdown of miR-92a significantly inhibited HeLa cell viability and invasion, whereas overexpression of miR-92a enhanced these cellular events. Based on these findings and others, we suggest that miR-92a may be a potential therapeutic target for cervical cancer growth and metastasis.

**DKK3**, a member of the dickkopf family, encodes a secreted protein containing two cysteine-rich regions (26). Through interacting with the Wnt signaling pathway, DKK3 has been identified to be involved in various biological processes, including embryonic development and tumorigenesis (27,28). The expression of DKK3 has been indicated to be frequently decreased in various cancers such as pancreatic cancer and breast cancer, and DKK3 has been suggested to function as an important tumor suppressor (19,20). A study by Ryu et al (29) reported that downregulation of DKK3 was associated with adverse clinical outcomes of cervical cancer. Furthermore, overexpression of DKK3 was revealed to inhibit cell growth and colony formation of cervical cancer cells (30). In the present study, bioinformatics analysis and luciferase reporter assay were conducted, which demonstrated that DKK3 is a direct target gene of miR-92a. Furthermore DKK3 protein expression was negatively mediated by miR-92a in HeLa cells. Additionally, overexpression of DKK3 significantly attenuated the effects of miR-92a upregulation on HeLa cell viability and
invasion, suggesting that miR-92a promotes cervical cancer cell viability and invasion via directly targeting DKK3. In fact, the targeting relationship between miR-92a and DKK3 has also been indicated in neuroblastoma (31). Therefore, the present study expands the understanding of miR-92a in the regulation of DKK3 in human cancer.

In the present study, mRNA and protein expression levels of DKK3 were significantly increased in cervical cancer tissues compared with matched adjacent non-tumor tissues. These findings were consistent with another study, Ryu et al (29) also reported that DKK3 was significantly downregulated in cervical cancer and demonstrated that low expression of DKK3 was associated with advanced clinical stage and poor 5-year disease-free survival rate of patients with cervical cancer. Furthermore, the present data indicated an inverse correlation between miR-92a and DKK3 expression levels in cervical cancer tissues. As DKK3 is a direct target gene of miR-92a and its expression was negatively regulated by miR-92a, we suggest that the increased miR-92a expression may contribute to the downregulation of DKK3 in cervical cancer.

In conclusion, to the best of our knowledge, the present study is the first to demonstrate that miR-92a promotes cell viability and invasion of cervical cancer cells through suppressing the protein expression of DKK3. These findings highlight the importance of the miR-92a/DKK3 axis in the clinical application for the treatment of cervical cancer in the future.

References